Aeterna Zentaris (NASDAQ:AEZS) Coverage Initiated at began coverage on shares of Aeterna Zentaris (NASDAQ:AEZSGet Free Report) (TSE:AEZ) in a research note issued on Friday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Aeterna Zentaris Stock Performance

Shares of NASDAQ:AEZS opened at $2.19 on Friday. The company has a market cap of $10.64 million, a P/E ratio of -0.46 and a beta of 1.56. Aeterna Zentaris has a one year low of $1.36 and a one year high of $3.38. The business’s 50-day simple moving average is $1.90 and its 200 day simple moving average is $1.95.

Aeterna Zentaris Company Profile

(Get Free Report)

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults.

Featured Articles

Receive News & Ratings for Aeterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeterna Zentaris and related companies with's FREE daily email newsletter.